Pharmaceutical composition comprising pyridazinyl-thiazolecarboxamide compound

Abstract

A compound useful as an active ingredient of a pharmaceutical composition for treatment of colorectal cancer (except for mismatch repair-deficient bowel cancer) is provided. In an embodiment, a compound useful as an active ingredient of a pharmaceutical composition for treatment of colorectal cancer (except for mismatch repair-deficient bowel cancer) related to activation of immune cells or colorectal cancer (except for mismatch repair-deficient bowel cancer) having resistance to anti-PD-1 antibody / anti-PD-L1 antibody therapy is provided. In addition, a pharmaceutical composition, comprising administering an effective amount of a compound, for example, a DGK ζ inhibitor, to the subject in combination with a combination therapy for treatment of colorectal cancer (except for mismatch repair-deficient bowel cancer) and / or non-small cell lung cancer is provide. The present inventors have conducted studies on a compound useful as an active ingredient of a pharmaceutical composition for treatment of colorectal cancer (except for mismatch repair-deficient bowel cancer), in an embodiment, for treatment of colorectal cancer (except for mismatch repair-deficient bowel cancer) related to activation of immune cells or colorectal cancer (except for mismatch repair-deficient bowel cancer) having resistance to anti-PD-1 antibody / anti-PD-L1 antibody therapy, and found that a pyridazinyl-thiazolecarboxamide compound has DGK ζ (DGKzeta) inhibitory effect, leading to completion of the present invention. The pyridazinyl-thiazolecarboxamide compound of the present invention has DGK ζ inhibitory effect, and can be used as a therapeutic agent for treatment of colorectal cancer (except for mismatch repair-deficient bowel cancer), in an embodiment, for treatment of colorectal cancer (except for mismatch repair-deficient bowel cancer) related to activation of immune cells or colorectal cancer (except for mismatch repair-deficient bowel cancer) having resistance to anti-PD-1 antibody / anti-PD-L1 antibody therapy. In addition, the pharmaceutical composition, comprising administering an effective amount of the pyridazinyl-thiazolecarboxamide compound of the present invention or a salt thereof to the subject in combination with a combination therapy can be used as a therapeutic agent for treatment of colorectal cancer (except for mismatch repair-deficient bowel cancer) and / or non-small cell lung cancer.

Images